Literature DB >> 10326049

High cost factors for leukaemia and lymphoma patients: a new analysis of costs within these diagnosis related groups.

C Quantin1, F Entezam, P Brunet-Lecomte, E Lepage, H Guy, L Dusserre.   

Abstract

STUDY
OBJECTIVE: To determine high cost factors to help managers and clinicians to analyse the reasons of adverse costs and provide indications for financial negotiation.
DESIGN: To locate high cost or long stay patients, the analysis was designed on the basis of a mixture of Weibull distributions. In this new model, the proportion of high cost patients was expressed according to the multinomial logistic regression, permitting the determination of high cost factors.
SETTING: The 1993 French reference database, constituted in the framework of the national study of DRG costs, conducted by the French Ministry of Health. The database of discharge abstracts recorded in 1993 in the Dijon public teaching hospital. PARTICIPANTS: The analyses were based on 1352 abstracts from the French reference database and 368 from the Dijon database concerning patients, aged 18 and over, suffering from leukaemia and lymphoma. MAIN
RESULTS: High cost and long stay factors were the same: number of stays, death, transfer, acute leukaemia, neutropenia, septicaemia, high dose aplastic chemotherapy, central venous catheterisation, parenteral nutrition, protected or laminar airflow room, blood transfusion, and intravenous antibiotherapy.
CONCLUSIONS: Taking into account high cost predictive factors, as shown in the case of leukaemia and lymphoma patients, would help to reduce the adverse effects of a prospective payment system.

Entities:  

Mesh:

Year:  1999        PMID: 10326049      PMCID: PMC1756772          DOI: 10.1136/jech.53.1.24

Source DB:  PubMed          Journal:  J Epidemiol Community Health        ISSN: 0143-005X            Impact factor:   3.710


  23 in total

1.  Contribution of a measure of disease complexity (COMPLEX) to prediction of outcome and charges among hospitalized patients.

Authors:  J M Naessens; C L Leibson; I Krishan; D J Ballard
Journal:  Mayo Clin Proc       Date:  1992-12       Impact factor: 7.616

2.  Admission and mid-stay MedisGroups scores as predictors of hospitalization charges.

Authors:  L I Iezzoni; A S Ash; G A Coffman; M A Moskowitz
Journal:  Med Care       Date:  1991-03       Impact factor: 2.983

3.  The relationship between severity of illness and hospital length of stay and mortality.

Authors:  S D Horn; P D Sharkey; J M Buckle; J E Backofen; R F Averill; R A Horn
Journal:  Med Care       Date:  1991-04       Impact factor: 2.983

4.  Severity of illness within DRGs. Homogeneity study.

Authors:  S D Horn; R A Horn; P D Sharkey; A F Chambers
Journal:  Med Care       Date:  1986-03       Impact factor: 2.983

5.  Measuring differences and similarities in hospital caseloads: a conceptual and empirical analysis.

Authors:  D A Dayhoff; J Cromwell
Journal:  Health Serv Res       Date:  1993-08       Impact factor: 3.402

6.  A study of the relationship between severity of illness and hospital cost in New Jersey hospitals.

Authors:  R F Averill; T E McGuire; B E Manning; D A Fowler; S D Horn; P S Dickson; M J Coye; D L Knowlton; J A Bender
Journal:  Health Serv Res       Date:  1992-12       Impact factor: 3.402

7.  Economic impact of diagnosis-related groups and severity of illness on reimbursement for central nervous system infections.

Authors:  H Froehlich; W R Jarvis
Journal:  J Pediatr       Date:  1991-05       Impact factor: 4.406

8.  Measuring severity of illness: six severity systems and their ability to explain cost variations.

Authors:  J W Thomas; M L Ashcraft
Journal:  Inquiry       Date:  1991       Impact factor: 1.730

9.  Relationship of physician ratings of severity of illness and difficulty of clinical management to length of stay.

Authors:  C Kelleher
Journal:  Health Serv Res       Date:  1993-02       Impact factor: 3.402

10.  Disease staging and PMCs. Can they improve DRGs?

Authors:  K A Calore; L Iezzoni
Journal:  Med Care       Date:  1987-08       Impact factor: 2.983

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.